New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2013
08:20 EDTENZYEnzymotec says Vayacog study results accepted for publication
Enzymotec announced the acceptance for future publication of its clinical study results evaluating the safety and effectiveness of Vayacog usage in non-demented elderly. The article manuscript titled "Phosphatidylserine containing omega-3 fatty acids may improve memory abilities in non-demented elderly with memory complaints: Results from an open-label extension" was accepted for publication in the peer-reviewed journal "Dementia and Geriatric Cognitive Disorders." During the study, a significant improvement in sustained attention and memory recognition was observed in subjects switching from placebo to Vayacog. Additionally, a significant improvement in CGI-C was observed in this group.
News For ENZY From The Last 14 Days
Check below for free stories on ENZY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2014
14:05 EDTENZYNeptune says '348 patent still valid, to appeal USPTO decision
Neptune Technologies & Bioressources (NEPT) announced that the United States Patent and Trademark Office, or USPTO, recently issued a Right of Appeal Notice in an inter partes reexamination of Neptune's '348 patent. Despite the USPTO's decision, the '348 patent is still valid as Neptune has the right to appeal, which it intends to do, the company said. "Enzymotec (ENZY), in yet another clear attempt to shift focus from the on-going International Trade Commission investigation of its infringement of other Neptune patents, issued a press release addressing the '348 Patent decision. However, Enzymotec failed to highlight that the decision has no impact on the ITC investigation into infringement of Neptune's other composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. Furthermore, the decision has no impact on Neptune's license agreements with Rimfrost and Aker BioMarine," said Neptune.
08:09 EDTENZYEnzymotec says USPTO issues final decision, rejects all claims in Neptune patent
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use